Journal
NEURON
Volume 101, Issue 5, Pages 774-778Publisher
CELL PRESS
DOI: 10.1016/j.neuron.2019.02.005
Keywords
-
Categories
Funding
- Department of Veterans Affairs (National Center for PTSD)
- NIAAA Center for the Translational Neuroscience of Alcohol [P50AA12870]
- Yale Center for Clinical Investigation [UL1 RR024139]
- Brain and Behavior Research Foundation
- NIMH [MH045481, MH093897, MH077681]
- State of Connecticut
- [P01HL131478]
Ask authors/readers for more resources
Ketamine is the first exemplar of a rapid-acting antidepressant with efficacy for treatment-resistant symptoms of mood disorders. Its discovery emerged from a reconceptualization of the biology of depression. Neurobiological insights into ketamine efficacy shed new light on the mechanisms underlying antidepressant efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
